{"log_id": 5305895604477378673, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 0.000604, "average": 0.990495, "min": 0.84789}, "location": {"width": 793, "top": 155, "height": 34, "left": 240}, "words": "单胺氧化酶抑制作用:利奈唑胺为一可逆的、非选择性的单胺氧化酶抑制剂。所以,利奈唑"}, {"probability": {"variance": 0.003287, "average": 0.985906, "min": 0.705649}, "location": {"width": 490, "top": 189, "height": 30, "left": 236}, "words": "胺与类肾上腺素能和5-羟色胺类药物有潜在的相互作用"}, {"probability": {"variance": 0.001723, "average": 0.989242, "min": 0.743668}, "location": {"width": 793, "top": 248, "height": 33, "left": 240}, "words": "肾上腺素能类药物:有些患者接受利奈唑胺可能使非直接作用的拟交感神经药物、血管加压"}, {"probability": {"variance": 9.1e-05, "average": 0.995452, "min": 0.950041}, "location": {"width": 796, "top": 278, "height": 33, "left": 238}, "words": "药或多巴胺类药物的加压作用可逆性地增加。已对其与常用的药物如苯丙醇胺和伪麻黄碱的"}, {"probability": {"variance": 4.1e-05, "average": 0.997307, "min": 0.959745}, "location": {"width": 794, "top": 309, "height": 29, "left": 240}, "words": "作用进行了研究。肾上腺素能类药物,如多巴胺或肾上腺素的起始剂量应减小,并逐步调整"}, {"probability": {"variance": 2.9e-05, "average": 0.996317, "min": 0.980605}, "location": {"width": 202, "top": 341, "height": 28, "left": 241}, "words": "至可起理想药效的水平"}, {"probability": {"variance": 0.003667, "average": 0.967603, "min": 0.74315}, "location": {"width": 795, "top": 397, "height": 33, "left": 240}, "words": "5-羟色胺类药物:在I期、II期和II期的临床研究中,未见利奈唑胺与5-羟色胺类药"}, {"probability": {"variance": 0.002278, "average": 0.986614, "min": 0.725792}, "location": {"width": 778, "top": 426, "height": 34, "left": 239}, "words": "物合用引起5-羟色胺综合征的报道。利奈唑胺合用5-羟色胺类药物,包括抗抑郁药,如"}, {"probability": {"variance": 0.000804, "average": 0.98993, "min": 0.820507}, "location": {"width": 795, "top": 456, "height": 34, "left": 239}, "words": "选择性5-羟色胺再摄取抑制剂( SSRIS),有5-羟色胺综合征的自发性报告。接受利奈唑胺"}, {"probability": {"variance": 0.004879, "average": 0.986158, "min": 0.562991}, "location": {"width": 751, "top": 486, "height": 34, "left": 241}, "words": "治疗的患者如同时服用5-羟色胺类药物应当按照一般注意事项中的要求进行严密监测"}, {"probability": {"variance": 0.001117, "average": 0.983826, "min": 0.813965}, "location": {"width": 793, "top": 545, "height": 38, "left": 243}, "words": "强CYP450诱导剂:在一项健康志愿者中的研究,利福平和口服利奈唑胺合用导致利奈唑胺"}, {"probability": {"variance": 0.008321, "average": 0.971725, "min": 0.411337}, "location": {"width": 795, "top": 577, "height": 34, "left": 241}, "words": "的Cmax降低21%,AUC12降低32%。这一相互作用的临床意义不明。其它肝酶强诱导剂"}, {"probability": {"variance": 0.005191, "average": 0.985256, "min": 0.53642}, "location": {"width": 785, "top": 608, "height": 34, "left": 251}, "words": "(如卡马西平、苯妥英、苯巴比妥),可能引起相似或稍轻的变化(见【药理毒理】、【药"}, {"probability": {"variance": 1e-06, "average": 0.998859, "min": 0.996774}, "location": {"width": 115, "top": 646, "height": 23, "left": 243}, "words": "物相互作用】"}, {"probability": {"variance": 0, "average": 0.999313, "min": 0.997979}, "location": {"width": 267, "top": 701, "height": 29, "left": 243}, "words": "药物与实验室检查的相互影响"}, {"probability": {"variance": 0.000704, "average": 0.991028, "min": 0.885425}, "location": {"width": 348, "top": 728, "height": 32, "left": 282}, "words": "没有关于本品可千扰实验室检查的报道"}, {"probability": {"variance": 7e-06, "average": 0.998603, "min": 0.989786}, "location": {"width": 233, "top": 791, "height": 26, "left": 251}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.000582, "average": 0.99455, "min": 0.849259}, "location": {"width": 756, "top": 815, "height": 35, "left": 285}, "words": "利奈唑胺及其代谢产物可分泌至哺乳期大鼠的乳汁中。乳汁中的药物浓度与母体的血浆"}, {"probability": {"variance": 0.002071, "average": 0.989088, "min": 0.70813}, "location": {"width": 793, "top": 846, "height": 36, "left": 246}, "words": "药物浓度相似。利奈唑胺是否分泌至人类的乳汁中尚不明确。由于许多药物都能随人类的乳"}, {"probability": {"variance": 0.000104, "average": 0.99439, "min": 0.957304}, "location": {"width": 386, "top": 881, "height": 31, "left": 243}, "words": "汁分泌,因此利奈唑胺应慎用于哺乳期妇女"}, {"probability": {"variance": 7.4e-05, "average": 0.996948, "min": 0.946751}, "location": {"width": 756, "top": 907, "height": 33, "left": 286}, "words": "尚未在妊娠妇女中进行充分的、严格对照的临床研究。只有潜在的益处超过对胎儿的潜"}, {"probability": {"variance": 4e-06, "average": 0.998655, "min": 0.992456}, "location": {"width": 285, "top": 943, "height": 26, "left": 248}, "words": "在风险时,才建议妊娠妇女应用"}, {"probability": {"variance": 0.000229, "average": 0.992652, "min": 0.958807}, "location": {"width": 112, "top": 1005, "height": 24, "left": 254}, "words": "【儿童用药】"}, {"probability": {"variance": 0.002365, "average": 0.989587, "min": 0.695686}, "location": {"width": 754, "top": 1027, "height": 35, "left": 289}, "words": "利奈唑胺用于治疗儿童患者下列感染时的安全性和有效性已得到以下研究的证实,包括"}, {"probability": {"variance": 8.1e-05, "average": 0.997765, "min": 0.94273}, "location": {"width": 794, "top": 1057, "height": 36, "left": 248}, "words": "在成年人中进行的充分的、严格对照的临床研究、儿童患者的药代动力学研究资料以及在"}, {"probability": {"variance": 0.010709, "average": 0.972171, "min": 0.496365}, "location": {"width": 793, "top": 1086, "height": 39, "left": 247}, "words": "011岁革兰阳性菌感染的儿童中进行的阳性药物对照的临床研究(见【适应症】、【用法用"}, {"probability": {"variance": 0.000265, "average": 0.993041, "min": 0.944435}, "location": {"width": 182, "top": 1125, "height": 26, "left": 249}, "words": "量】和【临床研究】)"}, {"probability": {"variance": 2e-06, "average": 0.999192, "min": 0.996183}, "location": {"width": 145, "top": 1155, "height": 27, "left": 337}, "words": "院内获得性肺炎"}, {"probability": {"variance": 1e-06, "average": 0.99911, "min": 0.997118}, "location": {"width": 266, "top": 1184, "height": 27, "left": 339}, "words": "复杂性皮肤和皮肤软组织感染"}, {"probability": {"variance": 0.000223, "average": 0.994483, "min": 0.911381}, "location": {"width": 697, "top": 1206, "height": 38, "left": 339}, "words": "社区获得性肺炎(另有一个由8个月至12岁患者参加的非对照研究的证据支持"}, {"probability": {"variance": 1.1e-05, "average": 0.997683, "min": 0.990162}, "location": {"width": 266, "top": 1243, "height": 31, "left": 340}, "words": "万古霉素耐药的屎肠球菌感染"}, {"probability": {"variance": 0.000251, "average": 0.99576, "min": 0.902401}, "location": {"width": 737, "top": 1269, "height": 35, "left": 311}, "words": "个在5至17岁儿童患者中进行的阳性对照研究证实了利奈唑胺对下列感染的安全性"}, {"probability": {"variance": 6e-06, "average": 0.998375, "min": 0.991797}, "location": {"width": 235, "top": 1306, "height": 29, "left": 255}, "words": "和有效性(见【临床研究】"}, {"probability": {"variance": 5.7e-05, "average": 0.996366, "min": 0.95678}, "location": {"width": 707, "top": 1327, "height": 37, "left": 341}, "words": "由对甲氧西林敏感的金黄色葡萄球菌和化脓性链球菌引起的非复杂性皮肤和皮肤"}, {"probability": {"variance": 2e-06, "average": 0.999019, "min": 0.996631}, "location": {"width": 106, "top": 1367, "height": 26, "left": 334}, "words": "软组织感染"}, {"probability": {"variance": 5.8e-05, "average": 0.996584, "min": 0.955853}, "location": {"width": 752, "top": 1387, "height": 40, "left": 296}, "words": "在经脑室腹膜分流术的儿童患者中得到的药代动力学资料显示,给予单剂或多剂利奈"}, {"probability": {"variance": 0.000172, "average": 0.994568, "min": 0.938007}, "location": {"width": 774, "top": 1419, "height": 38, "left": 254}, "words": "唑胺后,脑脊液(CSF)中的药物浓度差异较大,并未总能达到或维持脑脊液的治疗浓度"}, {"probability": {"variance": 1.8e-05, "average": 0.99679, "min": 0.983977}, "location": {"width": 564, "top": 1452, "height": 35, "left": 254}, "words": "因此,不推荐利奈唑胺经验性用于儿童患者的中枢神经系统感染"}, {"probability": {"variance": 2.9e-05, "average": 0.996116, "min": 0.98287}, "location": {"width": 143, "top": 1486, "height": 23, "left": 583}, "words": "第12页,共25页"}, {"probability": {"variance": 1.4e-05, "average": 0.99428, "min": 0.990571}, "location": {"width": 17, "top": 1516, "height": 17, "left": 344}, "words": "20"}], "language": 3}